Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial

Journal of Clinical Oncology

Volumn 32, Issue 6, 2014, Pages 513-518

  Schrag, Deborah ^a   Weiser, Martin R ^a   Goodman, Karyn A ^a   Gonën, Mithat ^a   Hollywood, Ellen ^a   Cercek, Andrea ^a   Reidy Lagunes, Diane L ^a   Gollub, Marc J ^a   Shia, Jinru ^a   Guillem, Jose G ^a   Temple, Larissa K F ^a   Paty, Philip B ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; CORONARY STENT; DISEASE FREE SURVIVAL; ECG ABNORMALITY; FEMALE; HEART ARRHYTHMIA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; RECURRENCE RISK; TOTAL MESORECTAL EXCISION; TREATMENT RESPONSE; TUMOR REGRESSION; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; PATHOLOGY; RECTUM TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PILOT PROJECTS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84898684426     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.7904     Document Type: Article

References (22)

1. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
3. Sauer R, Liersch T, Merkel S, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926-1933, 2012
4. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
5. Benson AB, Bekaii-Saab T, Chan E, et al: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 4, 2013
6. Roh MS, Yothers GA, O'Connell MJ, et al: The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 29:221s, 2011 (suppl; abstr 3503)
7. Chau I, Brown G, Cunningham D, et al: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668-674, 2006 (Pubitemid 46630432)
8. Fernandez-Martos C, Pericay C, Aparicio J, et al: Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 28:859-865, 2010
9. Cercek A, Weiser MR, Goodman KA, et al: Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. J Clin Oncol 28, 2010 (suppl; abstr 481)
10. Allegra CJ, Yothers G, O'Connell MJ, et al: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29:11-16, 2011
11. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19-23, 1997 (Pubitemid 27138353)
12. Quah HM, Chou JF, Gonen M, et al: Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 113:57-64, 2008 (Pubitemid 351976386)
13. Shia J, Guillem JG, Moore HG, et al: Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 28:215-223, 2004 (Pubitemid 38124730)
14. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
15. Andre T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
16. Bosset JF, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114-1123, 2006 (Pubitemid 44394918)
17. Khrizman P, Niland JC, ter Veer A, et al: Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: A national comprehensive cancer network analysis. J Clin Oncol 31:30-38, 2013
18. Perez K, Pricolo V, Vrees M, et al: A phase II study of complete neoadjuvant therapy in rectal cancer (CONTRE): The Brown University Oncology Group. J Clin Oncol 30, 2013 (suppl 4; abstr 335)
19. Fernandez-Martos C, Safont M, Feliu J, et al: Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): A GEMCAD study. J Clin Oncol 29:30s, 2010 (suppl; abstr TPS196)
20. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
21. Bruheim K, Guren MG, Skovlund E, et al: Late side effects and quality of life after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 76:1005-1011, 2010
22. Temple LK, Wong WD, Minsky B: The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Radiat Oncol 13:469-477, 2003 (Pubitemid 37377608)